Focus: Almatica Pharma is a newly public (2024) small-molecule pharmaceutical company headquartered in Morristown, NJ, focused on neurology, infectious diseases, cardiovascular, and psychiatry indications. The company operates a portfolio of established branded and generic products with significant revenue concentration in legacy assets.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Stable — net -3 jobs in 30d
6 added, 9 removed. Backfill posture.
Almatica is a stable but stagnant asset-management play suitable only for candidates prioritizing cash-paying employment over career development; the empty pipeline and imminent patent cliffs create high restructuring risk within 3-5 years.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Anchor product representing 53% of revenue but facing imminent generic erosion with no disclosed LOE date.
Help build intelligence for Almatica Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Almatica Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only product with extended patent protection (LOE 2034) providing decade-long revenue visibility; however, modest revenue scale ($1M) limits upside.
Combination antihypertensive product in mature, competitive market with minimal revenue and approaching exclusivity loss.
9 discontinued, 23 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
+5 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo